Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proteome-based Personalized Immunotherapy in Recurrent GBM
NCT01759810Phase 3Unknown
- Sponsor
- NeuroVita Clinic
- Start
- Dec 2012
- Primary completion
- Dec 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine, hematopoietic stem cells in glioblastoma multiforme (GBM), sponsored by NeuroVita Clinic. Status: unknown.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccinehematopoietic stem cells
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01759810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01759810.